logo

VRTX

Vertex Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)

VRTX fundamentals

Vertex Pharmaceuticals (VRTX) expects to report earnings on Feb 12, 2026, with estimated revenue of 3.18B (YoY +9.30%), and EPS at 5.1058 (YoY +28.29%).
Revenue estimate / YoY
3.18B
+9.30%
EPS estimate / YoY
5.1058
+28.29%
Report date
Feb 12, 2026
Earnings Call
4:30 PM on Feb 12, 2026
Meeting link.
EPS
Revenue

Revenue & Expenses

VRTX has released its 2025 Q3 earnings report, with revenue of 3.08B, reflecting a YoY change of 10.99%, and net profit of 1.08B, showing a YoY change of 3.59%. The Sankey diagram below clearly presents VRTX's revenue sources and cost distribution.

Key Indicators

Vertex Pharmaceuticals (VRTX) key financial stats and ratios, covering profitability, financial health, and leverage.
Vertex Pharmaceuticals (VRTX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Vertex Pharmaceuticals (VRTX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Vertex Pharmaceuticals (VRTX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Vertex Pharmaceuticals (VRTX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Vertex Pharmaceuticals (VRTX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield